Chiang Jia Li,Harry Rogoff,Youzhi Li,Jifeng Liu,Wei Li
申请号：
US15655366
公开号：
US20180030022A1
申请日:
2017.07.20
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors； to methods of using such compounds to treat refractory, recurrent, or metastatic cancers； to methods of selective killing cancer cells by using such compounds with specific administration regimen； to methods of targeting cancer stem cells by inhibiting Stat3 pathway； to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity； and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
